We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter's (BAX) Vital Edge Program Aids Patient Blood Management
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) recently collaborated with AdventHealth Tampa to develop customized hemostasis strategies that can aid in the latter’s clinical, operational and financial goals. This has been made possible with the help of Baxter’s Vital Edge program.
Notably, Vital Edge is a data-backed, evidence-based intraoperative hemostasis management program that has been created to enable hospitals and health care providers to boost hemostasis utilization practices. These practices make an impact on three interconnected aspects of surgical care — clinical efficiency, operational efficacy and financial performance.
This partnership is likely to strengthen Baxter’s Advanced Surgery segment.
Significance of the Collaboration
It is important to mention here that bleeding during surgery can result in higher complication rates that include surgical revisions and transfusions, thereby leading to higher resource utilization and costs. In this ever-changing environment, patient blood management is an extremely important component when it comes to providing high quality care at a lower cost.
On the back of Vital Edge, Baxter’s Advanced surgery team collaborates with hospitals to detect and educate on opportunities to upgrade usage of hemostatic agents to minimize intraoperative blood loss and product waste, thereby improving outcomes and reducing costs.
In fact, with the help of Vital Edge, AdventHealth Tampa will realize around $0.2 million in annual savings.
Market Prospects
Per a report by MarketsandMarkets, the global patient blood management market is anticipated to be worth $15.3 billion in 2024, witnessing a CAGR of 7.4% during the forecast period (2019-2024). Growing prevalence of blood disorders and higher number of blood donations and blood donors will drive the market during the forecast period.
Recent Developments
In November, Baxter announced the expansion of its sterile fill/finish manufacturing facilities located in Bloomington, IN, which is being jointly funded by Baxter and client investment. Notably, the construction of the planned expansion of the existing facility infrastructure worth $50 million is anticipated to be completed in 2021. For investors’ note, the Bloomington facilities are operated by Baxter’s BioPharma Solutions business.
In the same month, the company attained FDA approval for the Homechoice Claria automated peritoneal dialysis (APD) system with Sharesource connectivity platform. It is worth mentioning here that the clearance comes on the heels of the recent finalization of the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) payment model, the goal of which is to drastically increase the number of new patients with kidney failure who receive home dialysis and/or organ transplants.
Price Performance
Over the past year, shares of this Zacks Rank #4 (Sell) stock company have lost 4.4% against the industry’s rise of 5.4%.
Merit Medical has a projected long-term earnings growth rate of 12.6%.
Align Technology has an estimated long-term earnings growth rate of 18.3%.
Thermo Fisher has a projected long-term earnings growth rate of 18%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Baxter's (BAX) Vital Edge Program Aids Patient Blood Management
Baxter International Inc. (BAX - Free Report) recently collaborated with AdventHealth Tampa to develop customized hemostasis strategies that can aid in the latter’s clinical, operational and financial goals. This has been made possible with the help of Baxter’s Vital Edge program.
Notably, Vital Edge is a data-backed, evidence-based intraoperative hemostasis management program that has been created to enable hospitals and health care providers to boost hemostasis utilization practices. These practices make an impact on three interconnected aspects of surgical care — clinical efficiency, operational efficacy and financial performance.
This partnership is likely to strengthen Baxter’s Advanced Surgery segment.
Significance of the Collaboration
It is important to mention here that bleeding during surgery can result in higher complication rates that include surgical revisions and transfusions, thereby leading to higher resource utilization and costs. In this ever-changing environment, patient blood management is an extremely important component when it comes to providing high quality care at a lower cost.
On the back of Vital Edge, Baxter’s Advanced surgery team collaborates with hospitals to detect and educate on opportunities to upgrade usage of hemostatic agents to minimize intraoperative blood loss and product waste, thereby improving outcomes and reducing costs.
In fact, with the help of Vital Edge, AdventHealth Tampa will realize around $0.2 million in annual savings.
Market Prospects
Per a report by MarketsandMarkets, the global patient blood management market is anticipated to be worth $15.3 billion in 2024, witnessing a CAGR of 7.4% during the forecast period (2019-2024). Growing prevalence of blood disorders and higher number of blood donations and blood donors will drive the market during the forecast period.
Recent Developments
In November, Baxter announced the expansion of its sterile fill/finish manufacturing facilities located in Bloomington, IN, which is being jointly funded by Baxter and client investment. Notably, the construction of the planned expansion of the existing facility infrastructure worth $50 million is anticipated to be completed in 2021. For investors’ note, the Bloomington facilities are operated by Baxter’s BioPharma Solutions business.
In the same month, the company attained FDA approval for the Homechoice Claria automated peritoneal dialysis (APD) system with Sharesource connectivity platform. It is worth mentioning here that the clearance comes on the heels of the recent finalization of the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) payment model, the goal of which is to drastically increase the number of new patients with kidney failure who receive home dialysis and/or organ transplants.
Price Performance
Over the past year, shares of this Zacks Rank #4 (Sell) stock company have lost 4.4% against the industry’s rise of 5.4%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Merit Medical Systems, Inc. (MMSI - Free Report) , Align Technology, Inc. (ALGN - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical has a projected long-term earnings growth rate of 12.6%.
Align Technology has an estimated long-term earnings growth rate of 18.3%.
Thermo Fisher has a projected long-term earnings growth rate of 18%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>